SEC Comment Letter for Viridian Therapeutics, Inc.\DE (VRDN) (CIK 0001590750) (VRDN) — Nov 10, 2021
Viridian Therapeutics, Inc.\DE (VRDN) (CIK 0001590750)
Date: Nov. 10, 2021 · CIK: 0001590750 · Accession: 0000000000-21-013676
AI Filing Summary & Sentiment
File numbers found in text: 333-260859
Letter
United States securities and exchange commission logo November 10, 2021 Jonathan Violin, Ph.D. President and Chief Executive Officer Viridian Therapeutics, Inc. 221 Crescent Street, Suite 401 Waltham, MA 02453 Re:Viridian Therapeutics, Inc. Registration Statement on Form S-3 Filed November 8, 2021 File No. 333-260859 Dear Dr. Violin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Davis at 202-551-4385 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan A. Murr, Esq.
Show Raw Text
United States securities and exchange commission logo
November 10, 2021
Jonathan Violin, Ph.D.
President and Chief Executive Officer
Viridian Therapeutics, Inc.
221 Crescent Street, Suite 401
Waltham, MA 02453
Re:Viridian Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 8, 2021
File No. 333-260859
Dear Dr. Violin:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Michael Davis at 202-551-4385 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ryan A. Murr, Esq.